# Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Study · id `cardio:ct-nct02906709` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02906709](<https://clinicaltrials.gov/study/NCT02906709>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02906709

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.

## Technical summary

Registry record NCT02906709. Randomized; double masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-08-21 (actual). Results posted on 2019-09-19.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 184 participants (enrolled count; ClinicalTrials.gov record NCT02906709, source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)
- Started: 2016-10-17 (actual) (ClinicalTrials.gov record NCT02906709, source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)
- Primary completion: 2018-08-21 (actual) (ClinicalTrials.gov record NCT02906709, source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)
- Completion: 2018-08-21 (actual) (ClinicalTrials.gov record NCT02906709, source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)
- Results first posted: 2019-09-19 (ClinicalTrials.gov record NCT02906709, source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02906709-2019-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Placebo
- Intervention (Biological): Insulin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control (`cardio:pubmed-33512755`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4f9c3a686437ce3c92bde6ea5969cbfff129c5e2e3c76dfb984a22f8d4c5ca2a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
